Michael Foley

Cardiology Registrar | MRC Clinical Research Training Fellow | Imperial College London

[Michael Foley @MikeFoley89]

@djc795 @mmamas1973 @rallamee @mirvatalasnag @OKhaliqueMD @Hragy Thank you very much! The study is published today in @CircAHA

[Rahul Bahl @RahulBahl3]

Excellent presentation by @MikeFoley89 at #TCT2024 on physiology stratified analysis of ORBITA-2. FFR and iFR clearly predict the placebo controlled benefit of PCI. Especially in those with typical symptoms. @rallamee @SukhNijjer @RicardoPetraco

[Shayna Chotai @ShaynaChotai]

It was such a pleasure to join @rallamee to talk all things ESC 2024
Thank you so much @TheLancet #chloewilson

https://t.co/fyKYOasxo1

[Peter Haworth @pajhaworth]

Cardiology research is “on FiRE” in Portsmouth today. 2 wonderful cases using in depth coronary physiology and imaging as part of the Orbita Fire study. As always super support from the wonderful @fiyyazAJ, Chris and team.

[Royal College of Anaesthetists @RCoANews]

🎉New NovPods!

This time @DoreEoin and Dr Duncan Kemp are joined by @RosannaEGrimes to navigate us through the world of obstetric anaesthesia.

Episode 1: A typical day on labour ward
Episode 2: Maternal physiology with @LaylaGuscoth

🎧 https://t.co/PbX22JKIHN
@OAAinfo

[Christopher Rajkumar @rajkumar_chris]

Should PCI be an option for first line management of stable angina symptoms?

Point and counterpoint in @CircOutcomes with final word from @bnallamo and @TCTMD

https://t.co/501Y7HHgKB

@rallamee

[Dr Peter O'Kane @DrPeterOKane]

🙏🏻 @rallamee for coming to @UHD_NHS today to proctor our first 4 coronary sinus reducer cases @ShockwaveIVL

Great to get clinical program started after #ORBITACOSMIC @TheLancet & important we can now offer symptom relief for angina beyond PCI/CABG/OMT 👏🏻👏🏻 great job whole team

[Christopher Rajkumar @rajkumar_chris]

Check out our journal club with @OPCILive on ORBITA-STAR and the symptom stratified analysis of ORBITA-2 @rallamee @FloSimader @ImperialNHLI

[Rasha Al-Lamee @rallamee]

Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Another n-of-1 trial that might have some interesting results. Well done @ShaynaChotai on achieving the first of many big milestones during your PhD!

[Dan McKenzie @danmckenzie73]

Thanks to @drtimwells and the @SalisburyDistr1 Cathlab team for making me so welcome. 2 patients now with coronary sinus reducers in place - something I didn’t believe would work until ORBITA-COSMIC showed it did! @ShockwaveIVL @rallamee @Mariathas83 @DrPeterOKane @MikeFoley89

[Michael Foley @MikeFoley89]

Proud of my friend @rajkumar_chris presenting the game changing ORBITA-STAR trial on the main stage at #EuroPCR2024. EuroPCR’s got talent winner - well deserved against excellent competition. @rallamee @mshunshin

[Michael Foley @MikeFoley89]

The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in @JACCJournals by @FloSimader and @rajkumar_chris. PCI isn’t a therapy for all symptoms, it’s a therapy for angina @rallamee @mshunshin

[Frank Harrell @f2harrell]

Proud to be a co-author with @rallamee @mshunshin on a 100% Bayesian clinical trial paper that also uses our latest longitudinal ordinal modeling approach, helped by the #rstats rmsb package: https://t.co/lLPCAPbPRC How can cardiologist Matthew Shun-Shin master all this?

[Fiyyaz Ahmed-Jushuf @fiyyazAJ]

Incredibly proud to celebrate @rallamee being awarded the Global CV Future Leader Award 2024 #GCVAwards. An exceptional mentor to us, who has also built a strong team of young researchers at Imperial College @mshunshin @rajkumar_chris @MikeFoley89 @FloSimader @ShaynaChotai

[Michael Foley @MikeFoley89]

https://t.co/gqUY8J8uOM

Read our paper here @rallamee @rajkumar_chris @FloSimader @fiyyazAJ

[Michael Foley @MikeFoley89]

I’m delighted to see our paper highlighted by TCT MD. Our belief in a therapy is associated with how intuitive it seems. This may subconsciously influence the threshold we set for randomised data. We should keep this in mind as we appraise procedures, new and old. @rallamee

[Michael O'Riordan @mpjORIORDAN]

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective https://t.co/wjvWt0oy0F

[Eoin Dore @DoreEoin]

🚨 🚨
Please share with starting Novices for a warm welcome into the world of anaesthesia. The links have some feedback on them,if you’ve had a listen please leave your thoughts. What would you want to be in season 2? @drjonchambers1 @hasyourregtried @doctorhelgi @LaylaGuscoth

[Michael Foley @MikeFoley89]

Delighted to see our ORBITA-COSMIC design paper published in Eurointervention. Now for the results! My thanks as ever to my supervisors and the incredible ORBITA team @rallamee @mshunshin @rajkumar_chris @fiyyazAJ @FloSimader @drgrahamcole @ProfDFrancis

[Davide Capodanno @DFCapodanno]

Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized, placebo-controlled, double-blind trial investigating the efficacy of the CSR on quantified myocardial perfusion and stable angina. Here is the study rationale and design paper. https://t.co/wrshmjsGdh

[Rasha Al-Lamee @rallamee]

There is an unsung hero in the ORBITA family and we don’t do forgotten heroes. @mshunshin is the cleverest man I know and responsible for all the statistics and beautiful figures in ORBITA-2 (with a little help from my RAL chart). Give this man a round of applause!

[Rasha Al-Lamee @rallamee]

You couldn’t be prouder than me on this day. My ORBITA family